SEARCH

SEARCH BY CITATION

References

  • 1
    Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72:19341939.
  • 2
    Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9:741747.
  • 3
    Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, et al. Experience with the use of sirolimus in liver transplantation—Use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000; 6:734740.
  • 4
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, for the Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74:15601567.
  • 5
    Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001; 33:32343235.
  • 6
    Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74:10701076.
  • 7
    Snell GI, Levvey BJ, Chin W, Kotsimbos T, Whitford H, Waters KN, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21:540546.
  • 8
    Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995; 17:660665.
  • 9
    Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807815.
  • 10
    DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53:507513.
  • 11
    Johnson RWG, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777786.
  • 12
    Watson CJE, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, Calne R. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 2002; 67:505509.
  • 13
    Pridöhl O, Heinemann K, Hartwig T, Witzigmann H, Lamesch P, Fangmann J, et al. Low-dose immunosuppression with FK506 and sirolimus after liver transplantation: 1-Year results. Transplant Proc 2001; 33:32293231.
  • 14
    Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7:343351.
  • 15
    Graham RM. Cyclosporine: Mechanisms of action and toxicity. Cleve Clin J Med 1994; 61:308313.
  • 16
    Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999; 55:24072414.
  • 17
    Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33:590600.
  • 18
    Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20(suppl 3):S759S771.
  • 19
    Hostetter TH, Oslon JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85F93.
  • 20
    Bauer JH, Reams GP, Wu Z. The aging hypertensive kidney: Pathophysiology and therapeutic options. Am J Med 1991; 90(suppl):S21S27.
  • 21
    Steffes MW. Glomerular lesions of diabetes mellitus: Preventable and reversible. Nephrol Dial Transplant 1999; 14:1921.
  • 22
    Heffron TG, Smallwood GA, Davis L, Martinez E, Stieber AC. Sirolimus-based immunosuppressive protocol for calcineurin sparing in liver transplantation. Transplant Proc 2002; 34:15221523.
  • 23
    Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16(suppl 7):S49S51.
  • 24
    Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9:126129.
  • 25
    Wyeth-Ayerst Laboratories. Package insert. Rapamune oral solution (sirolimus). Princeton, NJ: Wyeth-Ayerst Laboratories, 1999.
  • 26
    Morelon E, Stern M, Israël-Biet D, Corréas J, Danel C, Mamzer-Bruneel M, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72:787790.